Related Experiment Video
Updated: Apr 16, 2026

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
Published on: August 9, 2022
Myeloperoxidase impairs the contractile function in isolated human cardiomyocytes
Judit Kalász1, Enikő T Pásztor1, Miklós Fagyas1
1Division of Clinical Physiology, Institute of Cardiology, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
Abstract:
We set out to characterize the mechanical effects of myeloperoxidase (MPO) in isolated left-ventricular human cardiomyocytes. Oxidative myofilament protein modifications (sulfhydryl (SH)-group oxidation and carbonylation) induced by the peroxidase and chlorinating activities of MPO were additionally identified. The specificity of the MPO-evoked functional alterations was tested with an MPO inhibitor (MPO-I) and the antioxidant amino acid Met. The combined application of MPO and its substrate, hydrogen peroxide (H2O2), largely reduced the active force (Factive), increased the passive force (Fpassive), and decreased the Ca(2+) sensitivity of force production (pCa50) in permeabilized cardiomyocytes. H2O2 alone had significantly smaller effects on Factive and Fpassive and did not alter pCa50. The MPO-I blocked both the peroxidase and the chlorinating activities, whereas Met selectively inhibited the chlorinating activity of MPO. All of the MPO-induced functional effects could be prevented by the MPO-I and Met. Both H2O2 alone and MPO + H2O2 reduced the SH content of actin and increased the carbonylation of actin and myosin-binding protein C to the same extent. Neither the SH oxidation nor the carbonylation of the giant sarcomeric protein titin was affected by these treatments. MPO activation induces a cardiomyocyte dysfunction by affecting Ca(2+)-regulated active and Ca(2+)-independent passive force production and myofilament Ca(2+) sensitivity, independent of protein SH oxidation and carbonylation. The MPO-induced deleterious functional alterations can be prevented by the MPO-I and Met. Inhibition of MPO may be a promising therapeutic target to limit myocardial contractile dysfunction during inflammation.
Insights
Myeloperoxidase (MPO) activation impairs cardiomyocyte function by altering active and passive forces and calcium sensitivity. These detrimental effects, independent of protein oxidation, can be prevented by MPO inhibition, suggesting a therapeutic target for inflammation-induced heart dysfunction.
Area of Science:
- Cardiovascular Biology
- Biochemistry
- Cell Physiology
Background:
- Myeloperoxidase (MPO) is an enzyme implicated in inflammatory responses.
- Oxidative stress and protein modifications are key factors in cardiovascular dysfunction.
Purpose of the Study:
- To investigate the mechanical effects of MPO on human cardiomyocytes.
- To identify MPO-induced myofilament protein modifications and their functional consequences.
- To evaluate the therapeutic potential of MPO inhibition.
Main Methods:
- Isolated left-ventricular human cardiomyocytes were studied.
- Mechanical properties (active and passive force, Ca2+ sensitivity) were measured.
- MPO activity, protein carbonylation, and sulfhydryl group oxidation were assessed.
Main Results:
- MPO activation significantly reduced active force and Ca2+ sensitivity while increasing passive force.
- MPO-induced functional changes were independent of direct SH-group oxidation and carbonylation of actin, myosin-binding protein C, and titin.
- MPO inhibition and the antioxidant Met prevented MPO-induced cardiomyocyte dysfunction.
Conclusions:
- MPO activation directly impairs cardiomyocyte mechanical function and Ca2+ regulation.
- Targeting MPO may offer a novel therapeutic strategy to mitigate myocardial contractile dysfunction during inflammatory conditions.

